ABL1 and Parkinson disease: Although initial clinical trials of c‐Abl inhibitors failed, novel c‐Abl inhibitors thought to accumulate in the brain at concentrations sufficient to block c‐Abl are now being tested in the clinic and offer the opportunity to evaluate the potential of c‐Abl inhibition as a disease‐modifying therapy for patients with PD.